SCHEMBL16570474

SCHEMBL16570474

O=C1Cc2cc(Nc3ncc4ccn(Cc5cccnc5)c4n3)ccc2N1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL6 P41182 2/20 0.59
▸ PTK2 Q05397 10/20 0.58
▸ PTK2B Q14289 8/20 0.58
▸ SYK P43405 2/20 0.48
▸ JAK3 P52333 2/20 0.48
▸ AURKA O14965 1/20 0.48
▸ DCLK1 O15075 1/20 0.48
▸ PDPK1 O15530 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ ROCK2 O75116 1/20 0.48
▸ PRKD3 O94806 1/20 0.48
▸ MAP4K4 O95819 1/20 0.48
▸ EGFR P00533 1/20 0.48
▸ NTRK1 P04629 1/20 0.48
▸ PRKCG P05129 1/20 0.48
▸ LCK P06239 1/20 0.48
▸ FYN P06241 1/20 0.48
▸ CDK1 P06493 1/20 0.48
▸ LYN P07948 1/20 0.48
▸ RET P07949 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16570339 0.92 PTK2 (0.55) BCL6PTK2PTK2BSYKJAK3
SCHEMBL16570673 0.86 BCL6 (0.59) BCL6PTK2PTK2BSYKKDR
SCHEMBL16570355 0.85 PTK2B (0.61) BCL6PTK2PTK2BSYKJAK3
SCHEMBL16570363 0.82 PTK2 (0.51) BCL6PTK2PTK2BJAK3AURKA
SCHEMBL16570923 0.80 PTK2 (0.68) BCL6PTK2PTK2BJAK3AURKA
SCHEMBL16571235 0.80 PTK2 (0.51) BCL6PTK2PTK2BSYKJAK3
SCHEMBL16571003 0.78 PTK2 (0.65) BCL6PTK2PTK2BJAK3AURKA
SCHEMBL16570201 0.78 KIF11 (0.47) BCL6PTK2PTK2BCDK1ULK1
SCHEMBL16570395 0.78 ULK1 (0.51) BCL6PTK2PTK2BCDK1ULK1
SCHEMBL16571393 0.77 ULK1 (0.62) BCL6PTK2PTK2BSYKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN BCL6 704/4885PTK2 2/4885PTK2B 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback